Niagen Bioscience Reports Strong Q1 2025 Financial Results

An announcement from Niagen Bioscience ( (NAGE) ) is now available.

On May 7, 2025, Niagen Bioscience, Inc. reported its financial results for the first quarter of 2025, revealing a significant year-over-year increase in net sales by 38% to $30.5 million, driven by strong demand for its Tru Niagen® and Niagen® ingredient products. The company achieved a gross margin of 63.4% and net income of $5.1 million, marking a substantial improvement from the previous year. Additionally, Niagen Bioscience announced an increased full-year outlook for 2025, expecting net sales growth between 20% and 25%, and highlighted its strategic rebranding and expansion of its NAD+ precursor patent portfolio, reinforcing its leadership in the healthy aging sector.

Spark’s Take on NAGE Stock

According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.

Chromadex’s overall score reflects its strong financial performance with improved profitability and cash flow, despite revenue growth challenges. The stock shows positive technical momentum but is overvalued based on its P/E ratio. The promising outlook from the earnings call, despite some operational challenges, supports a favorable stock assessment.

To see Spark’s full report on NAGE stock, click here.

More about Niagen Bioscience

Niagen Bioscience, Inc. operates in the health and wellness industry, focusing on products that promote healthy aging. Its primary offerings include the Tru Niagen® supplement and Niagen® ingredients, which are nicotinamide riboside-based products aimed at enhancing NAD+ levels in the body. The company is positioned in the expanding NAD+ market and has a strong emphasis on research and development, as well as intellectual property related to NAD+ precursors.

Average Trading Volume: 988,449

Technical Sentiment Signal: Buy

Current Market Cap: $678.8M

Learn more about NAGE stock on TipRanks’ Stock Analysis page.